Kasperska-Zajac Alicja, Brzoza Zenon, Rogala Barbara
Clinical Department of Internal Diseases, Allergology and Clinical Immunology, Medical University of Silesia, ul. 3-go Maja 13-15, 41-800 Zabrze, Poland.
Vaccine. 2007 May 4;25(18):3595-8. doi: 10.1016/j.vaccine.2007.01.062. Epub 2007 Jan 29.
Patients suffering form house dust mite-sensitive persistent allergic rhinitis (PAR) seem to show changed platelet aggregability following mite allergen-specific immunotherapy (SIT). However, in patients with grass pollen-sensitive intermittent allergic rhinitis, platelet release reaction in vivo, measured by beta-TG, did not change significantly during the dose increase phase of subcutaneous SIT with grass pollen allergoids. The aim of this study was to evaluate the influence of SIT with house dust mite allergen extracts on the degree of circulating platelet activity in patients with PAR. The study comprised 14 patients sensitized to house dust mite allergens with PAR during the early phase of subcutaneous SIT with house dust mite allergen extracts-Dermatophagoides farinae 50 p.c. and Dermatophagoides pteronyssinus 50 p.c. (Novo-Helisen Depot, Allergopharma, Germany). SIT comprised subcutaneous injection of allergen extracts during approximately 3 months. Blood was collected before SIT, as well as immediately before, 30 min and 24 h after maximum dose injection. Plasma levels of PF-4 and beta-TG, platelet activation markers were measured using commercial ELISA kit. PF-4 and beta-TG basal levels were not significantly different between the patients and the healthy subjects. PAR patients treated with SIT showed no significant differences in plasma levels of the markers between the different points of the study. Thus, it seems that the degree of platelet activation measured by PF-4 and beta-TG does not change in PAR patients during hyposensitization with mite allergen extracts, after the maximum dose was reached.
患有屋尘螨敏感的持续性变应性鼻炎(PAR)的患者在接受螨过敏原特异性免疫疗法(SIT)后,血小板聚集性似乎发生了变化。然而,对于草花粉敏感的间歇性变应性鼻炎患者,在用草花粉变应原提取物进行皮下SIT剂量增加阶段,通过β-血小板球蛋白测量的体内血小板释放反应并未显著改变。本研究的目的是评估用屋尘螨过敏原提取物进行SIT对PAR患者循环血小板活性程度的影响。该研究纳入了14例在皮下注射屋尘螨过敏原提取物(粉尘螨50%和户尘螨50%,德国Allergopharma公司的Novo-Helisen Depot)早期阶段对屋尘螨过敏原致敏且患有PAR的患者。SIT包括在大约3个月内皮下注射过敏原提取物。在SIT前、最大剂量注射前、注射后30分钟和24小时采集血液。使用商用ELISA试剂盒测量血小板活化标志物PF-4和β-血小板球蛋白的血浆水平。患者和健康受试者之间PF-4和β-血小板球蛋白的基础水平无显著差异。接受SIT治疗的PAR患者在研究的不同时间点,这些标志物的血浆水平无显著差异。因此,在用螨过敏原提取物进行减敏治疗期间,在达到最大剂量后,通过PF-4和β-血小板球蛋白测量的血小板活化程度在PAR患者中似乎没有变化。